Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)
Stifel Nicolaus analyst Thomas Stephan maintained a Hold rating on Bausch + Lomb Corporation today and set a price target of $16.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Stephan covers the Healthcare sector, focusing on stocks such as TransMedics Group, Glaukos, and Alphatec Holdings. According to TipRanks, Stephan has an average return of 2.1% and a 40.00% success rate on recommended stocks.
In addition to Stifel Nicolaus, Bausch + Lomb Corporation also received a Hold from Barclays’s Matt Miksic in a report issued today. However, on the same day, Citi maintained a Buy rating on Bausch + Lomb Corporation (NYSE: BLCO).
Based on Bausch + Lomb Corporation’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.24 billion and a GAAP net loss of $71 million. In comparison, last year the company earned a revenue of $1.14 billion and had a GAAP net loss of $212 million
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLCO in relation to earlier this year. Last month, Sam Eldessouky, the EVP & CFO of BLCO bought 4,000.00 shares for a total of $68,520.00.
Read More on BLCO:
Disclaimer & DisclosureReport an Issue
- Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank
- Bausch + Lomb price target lowered to C$19 from C$21 at Citi
- Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating
- Bausch + Lomb reports Q1 adjusted EPS 5c, consensus 5c
- Bausch + Lomb raises FY26 revenue view to $5.420B-$5.530B from $5.375B-$5.475B
